^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MB-101

    i
    Other names: IL13Ra2-specific CAR, MB-101, IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocyte therapy, IL13Rα2‐specific CAR T cells
    Associations

    News

    Trials
    Company:
    Fortress
    Drug class:
    IL-13-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2ms
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases • Immune cell
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600 • CD123 expression
    |
    cyclophosphamide • fludarabine IV • MB-101
    2ms
    NCI-2014-01488: Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    CD123 expression
    |
    MB-101
    over1year
    Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (clinicaltrials.gov)
    P1, N=82, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    CD123 expression
    |
    MB-101
    almost2years
    Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma (clinicaltrials.gov)
    P1, N=82, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
    Trial completion date • Trial primary completion date
    |
    IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    CD123 expression
    |
    MB-101
    over2years
    Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma (clinicaltrials.gov)
    P1, N=30, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Nov 2025 | Trial primary completion date: Dec 2023 --> Nov 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 expression
    |
    MB-101
    4years
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Jonsson Comprehensive Cancer Center | Suspended --> Recruiting
    Clinical • Enrollment open • CAR T-Cell Therapy
    |
    BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
    over4years
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma (clinicaltrials.gov)
    P1, N=24, Suspended, Jonsson Comprehensive Cancer Center | Recruiting --> Suspended
    Clinical • Trial suspension • CAR T-Cell Therapy
    |
    BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
    5years
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • CAR T-Cell Therapy
    |
    BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous